|
Claims  |
|
|
We claim:
1. A method for the asymmetric degradation of DNA comprising
(a) generating DNA fragments by the application of restriction
endonucleases
(b) end-blocking one terminus of each of said fragments by the introduction
of a thionucleotide analog protecting group said protecting group being
capable of inhibiting exonuclease activity
(c) specifically degrading the non-protected terminus of said end-blocked
fragment by the application of exonucleases.
2. A method of claim 1 wherein said restriction endonucleases comprise
endonucleases which generate recessed 3' termini as a result of their
activity in combination with an endonuclease that generates recessed 5'
termini or flush ended termini.
3. A method of claim 2 wherein said recessed 3' termini generating
endonucleases are selected from the group consisting of Ava I, Ava II, Bam
HI, Bcl I, Bgl II, Bst EII, Dde I, Eco RI, Eco RII, Hind III, Hinf I, Hpa
II, Mbo I, Sal I, Sau 3A, Sau 96I, Taq I, Xba I and Xho I.
4. A method of claim 2 wherein said recessed 5' termini generating
endonucleases are selected from the group consisting of Bgl I, Cfo I, Dpn
I, Hae II, Hha I, Pst I, Pvu I, Kpn I, Sph I, Sst I, Sst II and Xor II.
5. A method of claim 2 wherein said flush termini generating endonucleases
are selected from the group consisting of Alu I, Bal I, Hae III, Hpa I,
Mbo II, Pvu II, Sma I and Tha I.
6. A method of claim 2 wherein said recessed 3' termini generating
endonuclease is Dde I and said recessed 5' termini generating endonuclease
is Pvu I.
7. A method of claim 1 wherein said thionucleotide analogs are nucleotide
thiotriphosphates.
8. A method of claim 7 wherein said thionucleotide analogs are selected
from the group of Sp diasteromers consisting of 2' deoxyadenosine
5'-O-(1-thiotriphosphate), 2' deoxyguanosine 5'-O-(1-thiotriphosphate, 2'
deoxythymidine 5'-O-(1-thiotriphosphate) and 2' deoxycytidine
5'-O-(1-thiotriphosphate).
9. A method of claim 8 wherein said thionucleotide analog is deoxyadenosine
5'-O-(1-thiotriphosphate).
10. A method of claim 1 wherein said thionucleotide analogs are introduced
on to the recessed 3'-termini by the treatment with DNA polymerase I.
11. A method of claim 1 wherein said non-protected terminus is degraded by
the action of Exonuclease III.
12. A method for the asymmetric degradation of DNA comprising
(a) generating DNA fragments with one recessed 3'OH terminus by the
application of restriction endonucleases
(b) end-blocking said recessed terminus by the introduction of a
thionucleotide protecting group said protecting group being capable of
inhibiting exonuclease activity
(c) specifically degrading the non-protected terminus of said end-blocked
fragment by the application of exonucleases.
13. A method of claim 12 wherein said restriction endonucleases comprise
endonucleases which generate recessed 3' termini as a result of their
activity in combination with an endonuclease that generates recessed 5'
termini or flush ended termini.
14. A method of claim 13 wherein said recessed 3' termini generating
endonucleases are selected from the group consisting of Ava I, Ava II, Bam
HI, Bcl I, Bgl II, Bst EII, Dde I, Eco RI, Eco RII, Hind III, Hinf I, Hpa
II, Mbo I, Sal I, Sau 3A, Sau 96I, Taq I, Xha I and Xho I.
15. A method of claim 13 wherein said recessed 5' termini generating
endonucleases are selected from the group consisting of Bgl I, Cfo I, Dpn
I, Hae II, Hha I, Pst I, Pvu I, Kpn I Sph I, Sst I, Sst II and Xor II.
16. A method of claim 13 wherein said flush termini generating
endonucleases are selected from the group consisting of Alu I, Bal I, Hae
III, Hpa I, Mbo II, Pvu II, Sma I and Tha I.
17. A method of claim 13 wherein said recessed 3'termini generating
endonuclease is Dde I and said recessed 5'termini generating endonuclease
is Pvu I.
18. A method of claim 12 wherein said thionucleotides are analogs selected
from the group consisting of Sp diasteromers comprising 2' deoxyadenosine
5'-O-(1-thiotriphosphate), 2' deoxyguanosine 5'-O-(1-thiotriphosphate), 2'
deoxythymidine 5'-O-(1-thiotriphosphate) and 2' deoxycytidine
5'-O-(1-thiotriphosphate).
19. A method of claim 18 wherein said thionucleatide analog is
deoxyadenosine 5'-O-(1-thiotriphosphate).
20. A method of claim 12 wherein said thionucleotides are introduced on to
the recessed 3' termini by the treatment with DNA polymerase.
21. A method of claim 12 wherein said non-protected terminus is degraded by
the action of Exonuclease III.
22. A method for the generation of single strands of DNA from double
stranded DNA comprising.
(a) generating DNA fragments by the application of restriction
endonucleases Dde I and Pvu I,
(b) end blocking the Dde I generated terminus by the introduction of 2'
deoxyadenosine 5'-O-(1-thiotriphosphate) by treatment with DNA polymerase
I,
(c) degrading the strands containing the unprotected 3' termini with
Exonuclease III for a sufficient period of time to effect the complete
degradation of said strand,
(d) recovering the remaining single strand of DNA.
23. A method for the controlled degradation of DNA from one end of the
molecule comprising
(a) generating DNA fragments by the application of restriction
endonucleases Dde I and Pvu I,
(b) end-blocking the Dde I generated terminus by the introduction of
2'-deoxyadenosine-5-O-(1-thiotriphosphate) by treatment with DNA
polymerase I,
(c) partially degrading the strand coating the unprotected 3' terminus with
Exonuclease III by incubating a fraction of the time necessary to
completely degrade the chain, terminating the Exonuclease III degradation,
degrading the resultant 5' single strand and with nuclease S1 thereby
reducing the length of said DNA fragment from a specific termini in a
controlled fashion.
24. In a method for the sequencing of DNA wherein chain growth is
terminated the improvement comprising generating single stranded DNA of
fixed length by:
(a) generating DNA fragments by the application of restriction
endonucleases Dde I and Pvu I,
(b) end blocking the Dde I generated terminus by introduction of 2'
deoxyadenosine 5'-O-(1-thiotriphosphate) by treatment with DNA polymerase
I,
(c) degrading the strands containing the unprotected 3' termini with
Exonuclease III for a sufficient period of time to effect the complete
degradation of said strand,
(d) recovering the remaining single strand of DNA.
25. In a method for the S1 nuclease mapping of RNA transcripts wherein
single stranded DNA is hybridized to RNA the improvement comprising the
generating of single stranded DNA of fixed length by:
(a) generating DNA fragments by the application of restriction
endonucleases Dde I and Pvu I,
(b) end blocking the Dde I generated terminus by introduction of 2'
deoxyadenosine 5'-O-(1-thiotriphosphate) by treatment with DNA polymerase
I,
(c) degrading the strands containing the unprotected 3' termini with
Exonuclease III for a sufficient period of time to effect the complete
degradation of said strand,
(d) recovering the remaining single strand of DNA.
26. In a method of site directed in vitro mutagenesis wherein partially
denatured double stranded DNA is incubated with single stranded DNA the
improvement comprising the generating of single stranded DNA of fixed
length by:
(a) generating DNA fragment by the application of restriction endonucleases
Dde I and Pvu I,
(b) end blocking the Dde I generated terminus by introduction of 2'
deoxyadenosine 5'-O-(1-thiotriphosphate) by treatment with DNA polymerase
I,
(c) degrading the strands containing the unprotected 3' termini with
Exonuclease III for a sufficient period of time to effect the complete
degradation of said strand,
(d) recovering the remaining single strand of DNA.
27. The method of claim 11 followed by degradation by S1 nuclease.
28. The method of claim 21 followed by degradation by S1 nuclease. |
|
|
|
|
Claims  |
|
|
Description  |
|
|
FIELD OF THE INVENTION
This invention relates to the field of molecular biology and particularly
to the art of recombinant DNA technology. More specifically, the invention
relates to a method by which double stranded DNA molecules may be
shortened asymmetrically, as well as to a method by which single stranded
molecules may be obtained from double stranded DNA.
BACKGROUND OF THE INVENTION
As is now well known, deoxyribonucleic acid (DNA) exists as a long
unbranched molecule consisting of many similar units known as nucleotides.
The individual nucleotides are arranged into two large polymeric chains
which are interwound to form the so-called double helical structure of
DNA. The DNA nucleotides are generally of four types characterized by
possessing one of four organic heterocyclic ring moieties often referred
to as bases. Two of the bases adenine (A) and guanine (G) belong to the
class of heterocyclic ring compounds known as purines while the other two
bases thymine (T) and cytosine(C) belong to the pyrimidine class of
heterocyclic rings. In addition to a base, each nucleotide contains a five
carbon sugar (pentose) called deoxyribose and a phosphate (PO.sub.4)
group.
A part of one chain of DNA may be represented by the structure:
##STR1##
By convention the carbon atoms which comprises the deoxyribose moiety are
given designations 1' to 5'. The polymer is formed through diester
linkages of the phosphate group to the 3' and 5' carbon atoms of adjacent
pentose residues. This configuration results in the chain possessing a
free phosphate group at the 5' terminus and a free OH group at its 3'
terminus. Because of this arrangement of atoms the polynucleotide chain is
said to have polarity, that is one end of the molecule is distinguishable
from the other, much as the two ends of a bar magnet would be
distinguishable.
In its native form, DNA is comprised of two polynucleotide chains arranged
such that the bases of the two chains are oriented towards the center of
the molecule and the sugar-phosphate groups oriented to the outside of the
molecule.
More specifically, the bases are oriented in a complementary fashion so
that the specific purine G is always opposite the specific pyrimidine C
and the specific purine A is always opposite a specific pyrimidine T. Each
A.dbd.T or G.tbd.C base pair is stabilized by two and three hydrogen bonds
respectively. The sugar-phosphate groups, often referred to as the
"backbone" of the molecule are arranged in an antiparallel fashion, that
is to say if one chain is oriented 5'.fwdarw.3' to other chain is oriented
3'.fwdarw.5'. This specific arrangement is illustrated as follows:
##STR2##
As mentioned above in its native form DNA exists as a double helix; this is
the consequence of the fact that each base pair is displaced slightly
(.about.36.degree.) in axial rotation from the base pair adjacent to it.
The molecule thus makes one complete spiral turn every ten base pairs
resulting in the well-known double helical structure shown in FIG. 6.
DNA molecules are large, chemically stable and easily replicated and as
such are ideally suited to function as the storage form of genetic
information. For example, most of the genetic repertoire of the bacteria
E. coli is contained within a single DNA molecule composed of
approximately 4.2.times.10.sup.6 nucleotide base pairs.
The flow of genetic information in cells is well known. The information
directing the biosynthesis of any protein is encoded in the sequences of
DNA nucleotides known as a gene.
Transcription is the process by which the retrieval of information is
begun. Transcription involves the resynthesis of the information in the
form of another type of nucleic acid called ribonucleic acid (RNA). One
type of RNA, messenger RNA (mRNA), transports the information to the site
of protein synthesis called a ribosome.
Once the mRNA is synthesized from the gene, the process of protein
synthesis may begin. This process is essentially one of molecular
decoding, in which the nucleotide sequence of the mRNA provides a template
for the synthesis of a particular protein. Since there is a change from a
nucleic acid language into that of a protein language, this process of
protein synthesis appropriately is referred to as translation. Continuing
the analogy a bit further, it would be appropriate to think of the
constituents of the nucleic acids, the nucleotides, as representing the
alphabet of the nucleic acid language and the amino acids, the building
blocks of proteins, as representing the alphabet of the protein language.
During the process of translation not only are the languages changing but
the alphabets are changing as well. This is a particularly complex process
which is known to involve over 100 types of molecules. As the mRNA is
passed through the ribosome (much like the tape through a tape recorder)
groups of 3 nucleotides (codons) are positioned such as to orient
accessory RNA molecules, known as transfer RNA (tRNA), carrying a single
amino acid into the proper alignment for the addition of the amino acid to
the growing protein chain.
Of special interest with respect to the subject invention is the
relationship of the structure and function of DNA has to the application
of recombinant DNA (genetic engineering) technology.
One of the main objectives of genetic engineering experiments is to provide
to a recipient organism a source of genetic information which will permit
the recipient organism to perform a new function. Generally, this is
accomplished by providing the genetic information in the form of a piece
of DNA which has been isolated from another organism and chemically
integrated into the DNA which normally exists within the recipient
organism. The result of such a procedure is a molecular hybrid and is
often referred to as a chimeric DNA molecule (Chimera - Gk. mythol.--A
fire breathing monster usually represented as a composite of a lion, a
goat and a serpent.). Since the chimeric molecule is often replicated
(i.e. found in multiple copies) within the recipient organism, the DNA is
said to have been cloned. The construction of stable, functioning genetic
chimeras by means of genetic engineering techniques, involves a series of
in vitro and in vivo steps.
The source of DNA to be cloned may include viruses, bacteria, fungi, plants
or animals. This DNA is generally referred to as donor DNA and contains
the desired genetic information to be propagated. This DNA represents one
component of the chimera.
The other component of the chimera, the vector, is a segment of DNA into
which the donor DNA is integrated. This vector DNA, also referred to as
the cloning vehicle, is a segment of non-chromosomal DNA that is capable
of independent replication when placed within a microbe. The cloning
vehicles commonly used are derived from viruses, bacteria, fungi, plants
or a combination thereof.
For example, an early step in the genetic engineering process involves
integrating a fragment of donor DNA containing the desired genetic
information into an appropriate vector. Generally, this involves treating
both the vector DNA and the donor DNA with an enzyme (a restriction
endonuclease) which cleaves only at specific sites within the two DNAs.
Since the termini of the cleaved molecules are complementary, due to the
action of the restriction enzyme, the foreign DNA may be integrated at a
particular point within the plasmid. Optionally, this site of integration
itself will have been previously "engineered" so as to be nearby the
appropriate control sequences which will ensure the successful expression
(i.e. transcription and translation) of the integrated DNA. The last step
in the integration involves the enzymatic sealing of the phosphodiester
backbone of the DNA molecule employing the enzyme DNA ligase.
During the course of some recombinant DNA experiments, it is necessary to
generate a single stranded DNA molecule from a double stranded DNA
molecule. In addition it is often desirable to asymmetrically decrease the
length of a double stranded molecule in a progressive, controlled manner.
The instant invention provides a rapid and generally applicable method to
perform either of these manipulations.
BRIEF DESCRIPTION OF THE INVENTION
As mentioned above, DNA normally exists as a double stranded helix where
the two strands are arranged in an antiparallel fashion. Each strand
contains information complementary to that of the other. The current
method used to generate single strands is to separate the two strands with
chemicals and heat, and to isolate the two single strands by
electrophoresis through a porous matrix. This technique, called
electrophorectic strand separation, is time consuming (requiring an entire
day or more), often gives poor recovery of the single strands, is
ineffective for many DNA molecules, and often leaves contaminants with the
DNA which hinder subsequent experiments. Another method for generating
single strands calls for cloning the DNA into a single stranded bacterial
virus, called M13, which contains only one strand of the DNA. Although
this method is useful for very specialized applications, such as DNA
sequencing, it is time consuming to clone the DNA into M13 (taking several
days or more) and the DNA of interest is always attached to viral DNA. For
these reasons, M13 is not used to generate single strands for most
applications.
The subject invention provides a rapid, generally applicable method to
generate single strands from double stranded DNA by removing nucleotides
from only one end of the molecule. The technique calls for placing a
derivative of a normal component of DNA at one 3' end of a double stranded
DNA molecule. The derivative, an .alpha.-phosphorothioate nucleotide
(denoted as dNTP.alpha.S) has a sulfur substituted for an oxygen at the
.alpha.-phosphorus. A widely used commercially available enzyme, DNA
polymerase, will insert the dNTP.alpha.S into the 3' side of one end of a
double stranded DNA molecule, as long as that end has a recessed 3'
terminus. Recessed termini result because the strands at the end of the
DNA molecule are not of equal length, when the 5' strand overlaps the 3'
strand, the 3' strand is said to be recessed. Alternatively the 3' strand
may overlap resulting in a recessed 5' terminus. The ends can be made such
that only one of the strands is recessed at the 3' terminus by generating
the ends with the appropriate restriction endonucleases, (enzymes commonly
used for recombinant DNA manipulations). Because there are many
restriction enzymes with different sequence specificities currently
available, the election of a specific one to give a 3' recessed terminus
would be a matter to be practiced by an art skilled worker.
By no means exhaustive, examples of restriction endonuclease which generate
recessed 3' termini by recognizing defined sequences with double stranded
DNA include: Ava I, Ava II, Bam HI, Bcl I, Bgl II, Bst EII, Dde I, Eco RI,
Eco RII, Hind III, Hinf I, Hpa II, Mbo I, Sal I, Sau 3A, Sau 96I, Taq I,
Xba I, and Xho I. This activity is in constrast to other restriction
endonucleases which result in 5' recessed termini, such as Bgl I, Cfo I,
Dpn I, Hae III, Hha I, Kpn I, Pst I, Pvu I, Sph I, Sst I, Sst II, and Xor
II; or flush-ended termini such as Alu I, Bal I, Hae III, Hpa I, Mbo II,
Pvu II, Sma I and Tha I.
Once the dNTP.alpha.-S is situated at one of the 3' ends, treatment of the
DNA with exonuclease III (another widely used enzyme) will result in 3'
endwise degradation of the DNA from the side not containing a
dNTP.alpha.-S. In other words, the dNTP S protects the DNA from digestion
with exonuclease III, and if digestion is allowed to proceed to
completion, a single strand will be generated. Such a digestion takes on
the order of minutes to complete depending on the length of the DNA
fragment.
Alternatively, exonuclease III can be stopped before it reaches the end of
the DNA resulting in a partially single stranded/double stranded molecule.
Using another enzyme, S1 nuclease, which digests exclusively single
strands, the remaining single strand can be removed. In this way the
length of the DNA can be decreased by digestion from only one end, that is
asymmetrically. Other methods of decreasing the length of double stranded
DNA use enzymes or combinations of enzymes which degrade both ends of the
molecule simultaneously. These methods are, therefore, unsuitable if one
end of the molecule is required intact.
Advantages of the dNTP.alpha.-S method are that it is rapid, is effective
for DNAs of all lengths and sequences, results in yields of essentially
100%, and does not contaminate the DNA. It is a superior way to either
generate single stranded DNA from double strands or to asymmetrically
shorten double stranded DNA. An important attribute of the dNTP.alpha.S is
that they allow the DNA which contains them to be introduced directly into
cells because the analogs do not interfere with the enzymes the cells use
to replicate their DNA.
DETAILED DESCRIPTION OF THE DRAWINGS
FIG. 1a illustrates the sequential action of DNA polymerase I and
Exonuclease III on a fragment of DNA. The phosphorus of the dTTP that was
radioactively labelled is indicated by an asterisk and the dAMP.alpha.S is
indicated by an underline.
FIG. 1b represents an electrophoretic gel pattern of fragments of DNA
resulting from the treatment of Exonuclease III upon dAMP.alpha.S
containing and non-containing DNA molecules.
FIG. 2 shows the release of radioactive labelled phosphorous over time from
Exonuclease III treated dAMP.alpha.S capped and uncapped DNA molecules.
FIG. 3 represents an electrophoretic gel pattern of single and double
stranded DNA molecules.
FIG. 4a illustrates the ligation and restriction of a dAMP.alpha.S capped
DNA fragment.
FIG. 4b represents an electrophorectic gel pattern of fragments of DNA
after treatment with restriction enzymes Msp I and Bst EII.
FIG. 5a illustrates the use of dATP(.alpha.-S) to construct a truncated
form of plasmid pBR322.
FIG. 5b represents an electrophoretic gel pattern of DNA fragments of PB322
and truncated pBR322 after digestion with endonuclease Hae III.
FIG. 6 illustrates the double-stranded structure of DNA.
FIG. 7 illustrates the active substrate of DNA polymerase.
FIG. 8A illustrates the specificity of endonuclease Dde I.
FIG. 8B illustrates an S fragment after treatment with DNA polymerase I.
FIG. 9 illustrates two embodiments of the subject invention.
DETAILED DESCRIPTION OF THE INVENTION
During the polymerization of DNA single nucleotide subunits are added to
the existing DNA chain. The reaction can be represented by the formula:
##STR3##
where (dNMP).sub.n represents DNA, a polymer of dexoyribonucleoside
monophosphates of length n and PP.sub.i represents pyrophosphate. The
above reaction is well-known and has been shown to be catalyzed both in
vivo and in vitro by an enzyme known as DNA-dependent DNA polymerase. In
the bacterium E. coli, this enzyme is referred to as DNA polymerase I.
The demonstration of DNA polymerase activity in vitro, was very useful in
that it allowed for manipulation of experimental parameters such as
changes in reactant concentrations, salt and pH. Additionally, analogs of
the natural nucleoside triphosphates could be tested for the effect on
stimulation, or inhibition of DNA synthesis as well as to elucidate the
stereochemistry of the reaction mechanism.
Of particular interest with respect to the subject invention, are the
diastereomeric phosphorothioate analogs of the nucleoside triphosphates
specifically S.sub.p diasteromer of the deoxyribonucleoside
thiotriphosphate (dNTP.alpha.S) in which a sulfur atom is substituted for
an oxygen atom at the alpha phosphate. The structure of the analog and the
unmodified nucleotides are as follows:
##STR4##
It has been shown (P. M. J. Burgers and F. Eckstein J. Biol. Chem.
254(15):6889-93) that said analogs act as substrates for the E. coli, DNA
polymerase I and are incorporated into growing DNA chains at an efficiency
similar to that of the unmodified substrates.
Although the polymerization activity is apparently unaffected, quite
unexpectedly it has been found, as disclosed herein, that the activity of
certain nucleases (depolymerizing enzymes) are inhibited by said analogs.
Deoxyribonucleases (DNases) are DNA degrading enzymes and can be
categorized into two broad classes: exonucleases or endonucleases. As the
names imply exonucleases degrade DNA from the ends of the polymer. Certain
exonuclease exhibit a polarity of degradation activity, that is some
enzymes degrade from the 3' end of a strand to the 5' end, while others
degrade 5' to 3' and still other degrade both 5' and 3' ends
simultaneously. Endonucleases degrade DNA by causing strand breaks to
occur in the middle of a DNA molecule usually at specific nucleotide
sequences. Among this class are the well-known restriction endonucleases
which are so useful in recombinant DNA experiments. In addition to the
location and polarity of degradation, nuclease are also distinguishable in
their ability to degrade double stranded or single stranded DNA. Some of
these activities, as they relate to the subject invention, will be
discussed in detail below.
According to one embodiment of the invention, full length single stranded
DNA may be generated from a double-stranded template owing to the
differential effects of said analogs on the activity of various nucleases.
Exonuclease III degrades double stranded DNA specifically from the 3' ends
of the strands and is inactive against DNA containing dNTP[.alpha.S]
analogs (See Example I). To obtain an intact single stranded molecule from
a double stranded DNA sample, the analog must be incorporated into one
strand of the DNA but not the other. This differential affect is
accomplished because of the unique requirements of the enzyme used to
incorporate the analog into the DNA.
The enzyme used to incorporate the dNTP.alpha.S base is DNA polymerase I.
As mentioned above this enzyme will add nucleotides (both normal and the
analogs) to an existing piece of DNA. However the DNA must possess several
structure features in order to serve as a substrate for the enzyme. One
strand of the DNA must possess a free 3' OH group into which the incoming
nucleotide is attached; this is referred to as the primer strand.
Additionally the opposite strand must extend past the primer thus serving
as a template directing the insertion of a particular nucleotides
according to the base pairing rules described above. The active substrate,
a 3' recessed terminus, would have a configuration such as shown in FIG.
7.
This type of configuration is easily generated, as is well-known in the
art, by the action of some of the restriction enconucleases described
above. For example the endonuclease Dde I (isolated from Desulfovibrio
desulfuricans) possess the specificity shown in FIG. 8A.
After treatment with DNA polymerase I employing dCTP, dGTP, dTTP and
dATP.alpha.S the fragment would appear as shown in FIG. 8B and, whereupon
after treatment with Exonuclease III the unprotected 3' strand will be
degraded and the protected strand will not be subject to the action of the
exonuclease.
It will be obvious to those skilled in the art that the opposite end of the
molecule would possess the same configuration resulting from the action of
Dde I at the adjacent site. It is therefore preferable to generate the
fragments using two restriction enzymes one such as Dde I which generates
3' recessed termini and one other enzyme such as PvuI which would generate
5' recessed termini or PvuII which generates blunt ends and thus would not
form appropriate primers or templates for DNA polymerase I. The selection
of the appropriate combination, from the over 200 known endonucleases,
would depend on the specific parameters of the operation as would be
determined by the skilled artisan.
In another embodiment of the subject invention, the exonuclease III can be
stopped prior to complete digestion of the unprotected strands thus
yielding a double stranded DNA molecule with a single stranded "tail". The
single stranded portion may then be removed by the action of yet another
nuclease, S1, which is specific for single-stranded DNA. Employing this
feature of the invention the skilled artisan can effect a controlled
degradation DNA from one end of the molecule. (i.e. asymmetric
degradation)
The NTP thio analogs have been used extensively as tools for analysis of
the stereochemistry of enzyme mechanisms. For example, the mechanisms of
polymerase, kinases, exonucleases, and of nucleotidyl tranferases have
been explored with these compounds. Their significance for such studies is
that the stereochemistry of the reaction about the chiral phosphorus atom
can easily be determined. We disclose herein the utility of the
NTP(.alpha.S)'s for certain aspects of in vitro modification of DNA, with
emphasis on their potential as aids to recombinant DNA manipulations.
Surprisingly because the sulphur at the .alpha.-phosphate interferes with
some enzymatic functions but not others, modification of one end of a DNA
molecule with the analog makes the end inert to specific processes such as
exonuclease III digestion.
Other nucleotide analogs such as the dideoxynucleotides, when incorporated
into DNA fragments, have also been shown to inhibit the 3'-5' exonuclease
activity of DNA polymerase (Aktinson, M. R., et al. Biochem. 8:4897-4904
(1969)). These analogs are used extensively in the chain termination
method of DNA sequencing because once inserted they prevent incorporation
of additional nucleotides. Unlike the dNTP(.alpha.S), the
dideoxynucleotides are unattractive for use in asymmetrically blocking
digestion of DNA fragments. Because they lack the 3' hydroxyl group,
fragments with terminal dideoxynucleotides are inert to ligation.
Consequently, although double stranded fragments containing
dideoxynucleotides can be asymmetrically digested, they cannot be made
viable for in vivo functions.
A major use of the thionucleotides is the ability to generate single
stranded DNA from a double stranded fragment. Single stranded DNA of fixed
length is useful for several purposes including DNA sequencing by the
chain termination technique (Sanger, F., et al. Proc. Nat'l. Acad. Sci.
74:5463-67 (1977)), S1 nuclease mapping of RNA transcripts (Weaver, R. F.
Weismann C. Nucl. Acid Res. 7:1175-1193 (1979)), and site directed
mutagenesis (Green, C. Tibbets C. Proc. Nat'l. Acad. Sci. 77:2455-2459
(1980)). When an .alpha.-thionucleotide is inserted into only one end of a
fragment, limit digestion with exonuclease III destroys only the
complementary strand. Such treatment provides a full length single strand
and, if the complementary strand is desired, it can be obtained by
appropriate choice of a restriction site at the other end of the fragment
and of the .alpha.-thionucleotide used for the filling in reaction. Unlike
other methods currently used for generating single strands (e.g., gel
electrophoresis strand separation), the thio nucleotide procedure creates
intact single strands regardless of length or sequence.
Most importantly, DNA containing the thio analog is replicated in vivo and,
therefore, plasmids modified with this analog are competent for cellular
transformation. Since all four dNTP(.alpha.S) will function similarly in
regard to the instant invention, only the dATP.alpha.-S is exemplified
herein.
The two particular embodiments described above may be summarized by
reference to FIG. 9.
A part of the substance of this invention has been described in a recent
publication (S. D. Putney, et al. Proc. Nat'l. Acad. Sci 78(12): 7350-54
(1981)). This publication is hereby incorporated into the present
disclosure and made part thereof.
The following examples are provided to illustrate, but not limit the scope
of the instant invention.
EXAMPLE I
This example demonstrates the effectivenes of dATP.alpha.S in inhibiting
the action of exonuclease III.
To show that the presence of dAMP(.alpha.S) within one strand of a double
stranded fragment renders that strand resistant to exonuclease III
digestion, a 302 bp fragment of known sequence, with a Bst EII generated
end at one side and KpnI generated end at the other, was treated with DNA
polymerase I, dCTP, dGTP, (.alpha..sup.32 P)dTTP, and either
dATP(.alpha.S) or dATP (FIG. 1a).
The BstI II-Kpn I fragment was obtained by digesting the E. coli plasmid
pSP201 with Bst EII and Kpn I and electrophoresing the products through a
5% polyacrylamide gel as described by Maniatis, et al. (Bio. Chem.
14:3787-94 (1975). The DNA was visualized by UV shadowing and isolated
from the gel following the method Maxam & Gilbert (Meth. of Enz.
GT:499-560 (1980).
Plasmid PSP201 (which contains the 302 base pair Bst EII-Kpn I fragment)
was replicated, in E. coli. host KL386. Isolation and purification were
performed by cleared lysate followed by cesium chloride centrifugation as
described by Hockman (Cell 17:583-595 (1979)).
The dATP(.alpha.S) Sp diastereomer was prepared using the methods discussed
in Byrant F. N. & Benkovic S. J. (Biochem. 18:2825-2828 (1979)). Because
Bst EII leaves the 5' strand protruding, and Kpn I leaves the 3' end
protruding, dAMP(.alpha.S) was inserted at only the 3' end of the Bst EII
side of the fragment. Because (.alpha.-.sup.32 P)TTP was included as a
substrate, the fragments were labeled selectively at the Bst EII side and
dAMP(.alpha.S) was positioned between the end of the fragment and the
labeled dTMP. Due to the 3'-exonuclease activity of DNA polymerase I, the
3'-protruding strand of the Kpn I side was rendered flush. The result of
this treatment was, therefore, a blunt ended fragment with dAMP(.alpha.S)
located one nucleotide from one end.
The filling in reaction was done by incubating 1.5 g DNA for 30' at
18.degree. C. with 50 mM Tris-HCl, pH 8.0, 5 mM MgCl.sub.2, 10 mM
2-mercaptoethanol, 50 .mu.M dGTP and dCTP, 10 .mu.M .alpha.-.sup.32
P)dTTP, 50 .mu.M dATP(.alpha.S) or dATP and 0.75 units of the large
fragment of DNA polymerase (BRL). The products were purified by
polyacrylamide electrophoresis as described by Maniatis, et al. (Biochem.
14:3787-94 (1975)). To perform the exonuclease III reactions, 0.005 g DNA
was incubated in 6.6 mM Tris-HCl, pH 7.5, 6.6 mM MgCl.sub.2, 6.6 mM
2-mercaptoethanol, 50 mM NaCl, and 1.12 units of exonuclease III (BRL) at
22.degree. C. for the indicated times. The fragments were electrophoresed
(6% polyacrylamide with 7 M urea) according to the method of Maxam and
Gilbert (Methods Enzymol. 65:499-560 (1980)).
To verify that only one end of the fragment was labeled, it was restricted
with Bst NI (which cleaves 157 base pairs from the Bst EII end (FIG. 1a)).
This gave only one labeled fragment as visualized by electrophoresing the
products through a denaturing polyacrylamide gel. Thus, the fragment was
uniquely labeled and an experiment using the same fragment with dAMP
replacing dAMP(.alpha.S) gave identical results.
The fragments were treated with a 1:9 molar ratio of DNA to exonuclease
III. To monitor the extent of digestion, reaction products were
electrophoresed through a denaturing gel which was subsequently
autoradiographed. Because dAMP(.alpha.S) lies between the end of the
fragment and the labeled dTMP (FIG. 1a), the fragment will remain labeled
only if dAMP(.alpha.S) prevents removal of the labeled TMP by blocking
exonuclease III digestion from this end of the molecule. On the other
hand, loss of label should be rapid if dAMP(.alpha.S) does not inhibit
exonuclease III digestion.
The results are shown in FIG. 1b. Exonuclease III digestion was carried out
for 0, 0.5, 2.0 and 8.0 minutes (lanes 1-4, respectively). Because the
amount of radioactivity at each time point remains essentially unchanged,
loss of label is clearly prevented by the terminal dAMP(.alpha.S).
Identical digestions with the uncapped fragment revealed rapid loss of
label (lanes 5-8).
The extent of resistance of capped fragments to exonuclease III was
explored in another manner. A 5.3 kb fragment, with Bst EII 5'-overhang
(FIG. 1) at both ends, was filled in with dCTP, dTTP, (.alpha.-.sup.32
P)dGTP, and either dATP(.alpha.S) or dATP. These fragments (labeled at
both ends) were incubated with excess (0.2 mg of capped or uncapped
fragment 12.5 units of enzyme) and the release of label was monitored by
measuring TCA precipitable radioactivity. The results (FIG. 2) show that,
at both 22.degree. and 37.degree. C., the amount of radioactivity in the
capped fragment is almost unchanged during the duration of the reaction
(60 min.) while the label is rapidly lost (1 min.) from the uncapped
fragment. Thus, a single dAMP(.alpha.S) protects the end of a DNA fragment
from prolonged exonuclease III digestion.
EXAMPLE II
This example illustrates the generation of full length single stranded DNA
from a double stranded DNA sample.
A 130 bp fragment, produced by Dde I (5' overhang) and Pvu I (3' overhang)
cleavages, was filled in at the Dde I end with dAMP(.alpha.S) as in
Example I. FIG. 3 shows the results of exonuclease III digestion of the
130 bp Dde I-Pvu I fragment containing dAMP(.alpha.S) at one end. Lane 1
shows 0.016 .mu.g of undigested fragment and lane 2 contains 0.040 .mu.g
treated with 200 units exonuclease III per .mu.g. Exonuclease III
digestion produces single stranded DNA which migrates above the double
strands. Electrophoresis was through a 7.5% polyacrylamide gel and the DNA
was visualized with ethidium bromide staining. In an identical experiment
using uncapped fragment, no DNA was visible after exonuclease III
digestion.
EXAMPLE III
This example illustrates the unimpaired ability to perform routine
recombinant DNA procedures employing DNA fragments containing
dNTP.alpha.S.
The dAMP(.alpha.S) containing Bst EII-Kpn I fragment and the uncapped
fragment (from Example I) were incubated separately with T4 DNA ligase
under conditions which promote intramolecular flush end litigation. As
shown in FIG. 4a (wherein the label is indicated by an asterisk and the
dAMP(.alpha.S) is underlined), such a ligation joins the Bst EII and Kpn I
ends. To assay the extent of ligation, the products were restricted with
Msp I which cleaves the fragment 38 pairs from the Kpn I end. Following
restriction and electrophoresis through a denaturing gel, two labeled
bands are observed for both the capped and uncapped fragment (FIG. 4b,
lanes 1 and 3). One 302 bases in length, results from fragments which
underwent ligation. The other, 264 bases, is unligated fragment. This
experiment demonstrates that dAMP(.alpha.S), located only one nucleotide
from the site of joining, has no significant effect on the efficiency of
this ligation reaction. Ligation was performed with 0.006 .mu.g DNA (at a
concentration of 0.075 .mu.g/ml) in 50 mM Tris-HCl, pH 7.8, 8.7 mM
MgCl.sub.2, 1.0 mM ATP with 1.5 units T4 DNA ligase (BRL) for 16 hours at
22.degree. C. Products were analyzed using a 6% polyacrylamide gel with 7
M urea.
Fortuitously, when the fragments are circularized, the Bst EII restriction
site is regenerated (see FIG. 4a). This offers a test of whether
dAMP(.alpha.S) interferes with the recognition of a restriction
endonuclease. When the Msp I treated ligation products were restricted
with Bst EII and electrophoresed (FIG. 4b, lanes 2 and 4), the 302 bp
fragment disappeared and a new fragment appeared at 38 bp. Hence, the
presence of dAMP(.alpha.S) within the recognition site for this
endonuclease does not affect cleavage.
EXAMPLE IV
This example illustrates the usefulness of the instant invention for the
contraction of modified recombinant DNA reactors.
The role of plasmids in molecular cloning technology is well established.
By the use of restriction endonucleases, fragments of DNA are generated
that can be readily inserted into appropriately cleaved plasmids and then
introduced into host cells. Plasmid pB322 a well-known plasmid of E. coli
with a molecular weight of 2.7.times.10.sup.6 daltons (4362 nucleotides)
contains a single Pst I restriction site located with a gene coding for
ampicillin resistance as well as single sites for Bam HI and Sal I with a
gene for tetracycline resistance. There are also single sites for Eco RI,
Hind III and Aua I.
The design of the experiment is outlined in FIG. 5a. pBR322 was opened at
the unique Eco RI site and the recessed 3' ends were rendered flush with
DNA polymerase in the presence of dATP(.alpha.S) and dTTP. Restriction was
then performed with Hind III to generate a fragment with dAMP(.alpha.S) at
one end. Limited exonuclease III treatment followed by S1 nuclease (to
produce flush ends) resulted in forms of pBR322 which were shortened from
the end which lacked dAMP(.alpha.S). This treatment destroyed the region
conferring tetracycline resistance. The fragments were then ligated under
conditions which promote recircularization, and an ampicillin/tetracycline
sensitive host was transformed.
Selection was made either for ampicillin or for tetracycline resistance. No
clones exhibiting tetracycline resistance were found, but many were
isolated as ampicillin resistant. (A control experiment, where no
exonuclease III treatment was performed, revealed that clones carrying
pBR322 missing only the region between the Eco RI and Hind III sites are
tetracycline resistant.) This suggests that, due to dAMP(.alpha.S)
incorporation, exonuclease III digestion proceeded from the Hind III end
and not from the Eco RI end.
Plasmid DNA was isolated from one ampicillin resistant/tetracycline
sensitive clone to assess the nature and extent of exonuclease III
treatment. Upon restriction with Pst I (which cuts pBR322 once within the
Ap.sup.r region), it was found that the resulting plasmid was about 2.0 kb
in length and therefore 2.4 kb had been removed by exonuclease III.
Determination of the precise region removed by exonuclease III was made by
restricting the truncated plasmid with Hae followed by subsequent
electrophoresis of the products. Because Hae III cleaves pBR322 times
identification of the Hae III sites present in the modified plasmid reveal
the region missing from the original pBR322.
To generate the truncated plasmid, 2.0 .mu.g of pBR322 were restricted with
Eco RI and the fragment was incubated with dATP(.alpha.S), dTTP, and DNA
Polymerase. After restriction with Hind III, the fragments were incubated
with 20 units exonuclease III for 15' at 37.degree. C. as in Example 1.
Subsequent S1 nuclease treatment and ligation was performed essentially as
described in Roberts, T. M. and Laver G. D. (Meth. of Enz. 68:473-82
(1980)). The DNA was then used to transform cell strain KL386 according to
the procedure of Theall, et al. (Molec. Gen. Genets. 156:221-227 (1977)).
Selection was made for either ampicillin or tetracycline resistance. While
no clonies grew on tetracycline, 40 were percent on ampicillin. From one
of these, plasmid was isolated and 0.3 g was digested with Hae III and
electrophoresed in parallel with Hae III digested pBR322 on a 7.5%
polyacrylamide gel.
The results of Hae III digestion of intact pBR322, in parallel with those
of the shortened plasmid, are shown in FIG. 5b, lanes 1 and 2. All
fragments produced from Hae III cleavages within the region from
nucleotide 174 to 1949 in pBR322 are missing from the truncated plasmid,
while all other fragments are present. Hae III cleavage of the truncated
plasmid generates a fragment of approximate length 250, which is not
present in the pBR322 digest. Based on the lengths of the fragments
produced, it is estimated that the plasmid has a length of 2120
nucleotides which means that the exonuclease III digest proceeded to
approximately 160 bases from the origin of replication. Particularly
important is the presence in the truncated plasmid of the Hae III site at
position 4344, which is only 18 nucleotides from the original Eco RI site.
Another point is that the in vitro ligation preceeded even though the
dAMP(.alpha.S) was at the very end of the fragment. This confirms data in
Example 3 and shows that ligation is not affected by thio analog.
* * * * *
|
|
|
|
|
Description  |
|